Диссертация (1139560), страница 43
Текст из файла (страница 43)
Bernoulli J., Konkol Y., Vuorikoski H., Yatkin E. Effects of afala andantiestrogen ICI 182,780 in the model of hormone-dependent prostateinflammation. Bull Exp Biol Med. 2014; 156(6):807-9. doi: 10.1007/s10517014-2456-6.73. Berry S.J., Coffey D.S., Walsh P.C., Ewing L.L. The development of humanbenign prostatic hyperplasia with age. J Urol. 1984 Sep;132(3):474−9.74. Blumenthal M, ed. 1998. Therapeutic Guide to Herbal Medicines. TheComplete German Commission E Monographs. Austin, TX: AmericanBotanical Council.75.
Blumenthal,Busse,Goldberg,Gruenwald,Hall,Klein,Rister,Riggins (Editor). The Complete German Commission E Monographs,Therapeutic Guide to Herbal Medicines, 1st ed. 1998, Integrative MedicineCommunications, pub; Bk&CD-Rom edition, 1999.76. Bostanci, Y.; Kazzazi, A.; Momtahen, S.; Laze, J.; Djavan, B. Correlationbetween benign prostatic hyperplasia and inflammation. Curr. Opin. Urol.2013, 23, 5–10.77. Boyle PM, P., Robertson, C., Lowe, F. and Roehrborn, C.: Updated metaanalysis of clinical trials of Serenoa repens extract in the treatment ofsymptomatic benign prostatic hyperplasia. BJU Int, 93: 751, 200478. Buck A.C. Phytotherapy for the prostate.B.
J. U. 1996. Vol. 78. P. 325-326.79. Carbin B. E., Larsson B. and Lindahl O. (1990) Treatment of benign prostatichyperplasia with phytosterols. Br. J. Urol. 66, 639-641.80. Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, DaSilva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, KalinterisA, Marencak J, Perier A, Perrin P. Comparison of phytotherapy (Permixon)with finasteride in the treatment of benign prostate hyperplasia: a randomizedinternational study of 1,098 patients.
Prostate. 1996 Oct;29(4):231-40;discussion 241-2. PubMed PMID: 8876706.81. Chevalier G, Benard P, Cousse H, Bengone T. 1997. Distribution study ofradioactivity in rats after oral administration of the lipido/sterolic extract of303Serenoa repens (Permixon®) supplemented with [1-14C]-lauric acid, [114C]-oleic acid or [4-14C]-beta-sitosterol.
Eur J Drug Metab Pharmacokinet22:73-83.82. Claesson H. E., Odlander B., Jakobsson P. J. Leukotriene B4 in the immunesystem. Int J Immunopharmacol 1992; 14:441-449.83. Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression ofdihydrotestosterone in men with benign prostatic hyperplasia by dutasteride,a dual 5a-reductase inhibitor. J Clin Endocrin Metab 2004;89:2179−84.84. Coppenolle V.F. Slomianny C., Carpentier F., Le Bourhis X.
et al. Effects ofhyperprolactinemia on rat prostate growth: evidence of androgenodependence. Am. J. Physiol. Endokrinol. Metab. 2001; 280: 120–9.85. Costello LC, Feng P, Milon B, Tan M Franklin RB Role of zinc in thepathogenesis and treatment of prostate cancer: critical issues to resolve.Prostate Cancer and Prostatic Diseases. 2004; 7: 111–7.86. Crawford ED, Dall’Era J. Benign Prostatic Hyperplasia and the Progressionof Lower Urinary Tract Symptoms – a Review. US Renal & Genito-urinarydisease. 2006 p.44-4687. Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA,Meehan AG, Bautista OM, Noble WR, Kusek JW, Nyberg LM, RoehrbornCG; MTOPS RESEARCH Group.
Baseline factors as predictors of clinicalprogression of benign prostatic hyperplasia in men treated with placebo. JUrol. 2006 Apr;175(4):1422-688. CristoniA,MorazzoniP,BombardelliE.1997.Chemicalandpharmacological study on hypercritical CO2 extracts of Serenoa repens fruits.Fitoterapia 68:355-358.89. Cui D., Han G., Shang Y., Mu L., Long Q., Du Y. The effect of chronicprostatitis on zinc concentration of prostatic fluid and seminal plasma: asystematic review and meta-analysis.
Curr Med Res Opin. 2015; 31(9): 17639.30490. Dannies P.S. A serum prolactin-binding protein: implications for growthhormone . Trends Endocrinol Metab. 2001; 12(10): 427-8.91. De Bernardi di Valserra M, Tripodi AS, Contos S, Germogli R. 1994. Serenoarepens capsules: A bioequivalence study. Acta Toxicologica Et Therapeutica15:21-39.92. De Bernardi di Valserra M, Tripodi AS. 1994.
Rectal bioavailability andpharmacokinetics in healthy volunteers of serenoa repens new formulation.Arch Med Interna 46:77-86.93. Debruyne F, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, PerrinP, Teillac P, Vela-Navarrete R, Raynaud JP, Schulman CC.
Evaluation of theclinical benefit of permixon and tamsulosin in severe BPH patients-PERMALstudy subset analysis. Eur Urol. 2004 Jun; 45(6):773-9; Discussion 779-80.PubMed PMID: 15149751.94. Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent(Permixon) with an alpha-blocker (tamsulosin) in the treatment of benignprostatic hyperplasia: a 1-year randomized international study. Eur Urol2002;41:497–506.95. Debruyne F., Jardin A., Colloi D., Resel L., Witjes W., Delauche-CavallierM., et al. (1998) European ALFIN Study Group. Sustained-release alfuzosin,finasteride and the combination of both in the treatment of benign prostatichyperplasia. Eur Urol 34: 169–17596.
Di Silverio F, Flammia GP, Sciarra A, Caponera M, Mauro M, Buscarini M,Tavani M, D'Eramo G. Plant extracts in BPH. Minerva Urol Nefrol. 1993Dec;45(4):143-9. Review.97. Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S,D’Eramo G, Di Nicola S, Toscano V. 1998 . Effects of long-term treatmentwith Serenoa repens (Permixon®) on the concentrations and regionaldistribution of androgens and epidermal growth factor in benign prostatichyperplasia.
Prostate 37:77-83.30598. Di Silverio, F.; Bosman, C.; Salvatori, M.; Albanesi, L.; Proietti Pannunzi, L.;Ciccariello, M.; Cardi, A.; Salvatori, G.; Sciarra, A. Combination therapy withrofecoxib and finasteride in the treatment of men with lower urinary tractsymptoms (LUTS) and benign prostatic hyperplasia (BPH).
Eur. Urol. 2005,47, 72–78; discussion 78–79.99. Di Silverio F. Gentile V. Pastore A.L. Voria G. Mariotti G. Sciarra A.Benign Prostatic Hyperplasia: What About a Campaign for Prevention? UrolInt 2004;72:179–188100. DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM, BaoTing Zhu, Spaulding H, Goodin S, Toledano MB, Hait WN, Gallo MA. 1998.Clinical and biologic activity of an estrogenic herbal combination (PC- SPES)in prostate cancer. N Engl J Med 339:785-791.101. Djavan B.
The Correlation between Inflammation, BPH and ProstateCancer. European Urology Supplements 8 (2009) 863–864.102. Djavan B, et al. Longitudinal study of men with mild symptoms of bladderoutlet obstruction treated with watchful waiting for four years. Urology2004;64:1144–8.103. Djavan B, European Benign Prostatic Hyperplasia (BPH) - Report onBerlin-Chemie/Menarini - sponsored satellite symposium 2014. UrologyToday Vol 26. No 5.
Oct/Dec 2014 p. 18104. Djavan B, Shariat S, Omar M, Roehrborn CG, Marberger M. Doesprolonged catheter drainage improve the chance of recovering voluntaryvoiding after acute retention of urine (AUR)? Eur. Urol. 1998; 33(suppl1):110105. Djavan B, Y. K. Fong, T. Anagnostou, M. Waldert, H. Fajkovic, S.Marihart, M Harik, S Spaller, M. Remzi.
Progression delay in men with mildsymptoms of bladder outlet obstruction: a comparative study of phytotherapyand watchful waiting. World J Urol (2005) 23: 253–256306106. Elghamry MI, Hansel R. 1969. Activity and isolated phytoestrogen ofshrub palmetto fruits (Serenoa repens Small), a new estrogenic plant.Experientia 25:828-829.107. Emberton M et al. Benign prostatic hyperplasia as a progressive disease: aguide to the risk factors and options for medical management. Int J Clin Pract2008;62:1076–1086;108. Emberton M et al.
Risk stratification for benign prostatic hyperplasia(BPH) treatment. BJU Int 2011;107:876–880.109. Emberton M, Elhilali M, Matzkin H, et al. Symptom deterioration duringtreatment and history of AUR are the strongest predictors for AUR and BPHrelated surgery in men with LUTS treated with alfuzosin 10 mg once daily.Urology 2005;66:316–22.110. Emberton M. Definition of at-risk patients: dynamic variables. BJU Int2006;97(Suppl 2):12–5.111.
Engeler D. (Chair), Baranowski A.P., Borovicka J., Cottrell A.M., DinisOliveira P., Elneil S., Hughes J., Messelink E.J. (Vice-chair), de C. WilliamsA.C. Guidelines Associates: S. Goonewardene, M.P. Schneider.Guidelines onChronic Pelvic Pain. European Association of Urology, 2018.112. Epstein O.I., Beregovoy N.A., Sorokina N.S., Starostina M.V., ShtarkM.B., Gainutdinov Kh.
L., Gainutdinova T.Kh., Muhamedshina D.I.Membrane and synaptic effects of anti-S-100 are prevented by the sameantibodies in low concentrations // Frontiers in Biosciences. – 2003. – Vol.8.– P. 79–84.113. Ernst E, Resch KL: Concept of true and perceived placebo effects. BMJ1995, 311(7004):551- 553.114. Ernst E, Weihmayr T. Phytotherapy. 7: Applications in the urogenital tract.Fortschr Med. 1998 Sep 10;116(25):40-1.115. Falahatkar, S.; Mokhtari, G.; Pourreza, F.; Asgari, S.A.; Kamran, A.N.Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: A307prospective, randomized, double-blind, placebo-controlled study. Urology2008, 72, 813–816.116.
Furuya S., Kumamoto V., Vokoyama E. Dynamic aspect of obstructionhypertrophia prostatic. – J. Urol. Jap. – 1982. – V. 74. – p. 14-16.117. Galeone C, Pelucchi C, Talamini R, Negri E, Dal Maso L, Montella M,Ramazzotti V, Franceschi S, La Vecchia C. Onion and garlic intake and theodds of benign prostatic hyperplasia. Urology. 2007 Oct;70(4):672-6.PubMed PMID: 17991535.118. Gandaglia G, Zaffuto E, Fossati N, Cucchiara V, Mirone V, Montorsi F,Briganti A. The role of prostatic inflammation in the development andprogression of benign and malignant diseases.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
